Figure 1.
Inhibitory effect of Tα1-RGDR on LLC tumor model. (A) Tumor mass and entity photo of tumors (n = 9). (B) Tumor volume changes in different treatment groups (n = 9). LLC cells were injected subcutaneously into the left forelimb of C57BL/6 mice (5 × 105 cells/mouse). The tumor volume grew to 80–100 mm3, and the mice were randomly divided into four groups. Then, 0.1 mL of PBS, 0.31 mg/kg of Tα1-RGDR, and 0.25 mg/kg Tα1 were continuously injected subcutaneously every day, whereas 10 mg/kg of paclitaxel (Tax) was injected every other day. The mice were sacrificed, and the tumors were separated after the tumor volumes in the negative group reached approximately 1000 mm3. (C) Tumor weight in different groups (n = 9). (D) Mouse weight changes in different groups (n = 9). (E) Antitumor inhibition ratio of tumor mass and volume. (F) Histogram of IL-2 levels in mouse serum (n = 4). (G) Histogram of IFN-γ levels in mouse serum (n = 4). *p < 0.05, **p < 0.01, ***p < 0.001.